- Home
- FOLD vs LIVN Comparison
FOLD vs LIVN Comparison
Compare FOLD & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- LIVN
- Stock Information
- Founded
- FOLD 2002
- LIVN 1987
- Country
- FOLD United States
- LIVN United Kingdom
- Employees
- FOLD N/A
- LIVN N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FOLD Health Care
- LIVN Health Care
- Exchange
- FOLD Nasdaq
- LIVN Nasdaq
- Market Cap
- FOLD 2.5B
- LIVN 2.9B
- IPO Year
- FOLD 2007
- LIVN 1993
- Fundamental
- Price
- FOLD $9.41
- LIVN $57.65
- Analyst Decision
- FOLD Buy
- LIVN Strong Buy
- Analyst Count
- FOLD 7
- LIVN 7
- Target Price
- FOLD $30.29
- LIVN $60.00
- AVG Volume (30 Days)
- FOLD 5.0M
- LIVN 599.4K
- Earning Date
- FOLD 11-04-2025
- LIVN 11-05-2025
- Dividend Yield
- FOLD N/A
- LIVN N/A
- EPS Growth
- FOLD N/A
- LIVN N/A
- EPS
- FOLD N/A
- LIVN N/A
- Revenue
- FOLD $598,704,000.00
- LIVN $1,348,962,000.00
- Revenue This Year
- FOLD $21.12
- LIVN $10.10
- Revenue Next Year
- FOLD $21.23
- LIVN $7.90
- P/E Ratio
- FOLD N/A
- LIVN N/A
- Revenue Growth
- FOLD 21.28
- LIVN 8.63
- 52 Week Low
- FOLD $5.51
- LIVN $32.48
- 52 Week High
- FOLD $10.83
- LIVN $58.91
- Technical
- Relative Strength Index (RSI)
- FOLD 67.64
- LIVN 62.26
- Support Level
- FOLD $8.69
- LIVN $48.82
- Resistance Level
- FOLD $9.64
- LIVN $51.97
- Average True Range (ATR)
- FOLD 0.38
- LIVN 1.86
- MACD
- FOLD 0.03
- LIVN 0.14
- Stochastic Oscillator
- FOLD 82.68
- LIVN 85.96
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.